Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Cefuroxime Activity Against Gonorrhea

Efficacy and Pharmacodynamics

  • Cefuroxime axetil 1 g orally achieves only 95.9% cure rate (95% CI = 94.5%–97.3%) for urogenital and rectal gonorrhea, which falls below the minimum 95% lower confidence interval threshold required for recommended therapy, according to the CDC 1
  • For pharyngeal gonorrhea, cefuroxime is unacceptable with only 56.9% efficacy (95% CI = 42.2%–70.7%), making it essentially ineffective for this site, as reported by the CDC 1
  • The CDC guidelines from 1993 noted that cefuroxime axetil 1 g orally had "anti-gonococcal activity and pharmacokinetics less favorable than the 400 mg cefixime regimen" and was "not very effective against pharyngeal infections" 2, 3
  • Ceftriaxone 250 mg IM plus azithromycin 1 g orally (or doxycycline 100 mg twice daily for 7 days) is the only recommended first-line regimen, according to the CDC 4
  • Cefixime 400 mg orally remains superior to cefuroxime when ceftriaxone is unavailable, requiring mandatory test-of-cure at 1 week, although this information is from Praxis Medical Insights, an alternative source confirms cefixime's superiority over cefuroxime 5, 6